Loading...

MBRX MOLECULIN BIOTECH INC Other Situations 8-K Filing

MLCL

MBRX

MOLECULIN BIOTECH INC

(MBRX)

2025 8-K

Show Summary

Summary

Equity Offerings

Product Expansion

Notification of Delisting

Equity Offerings

Clinical Trials

Virtual KOL Event

New Product Launches

Compliance Notice

Financial Statements

Clinical Trials

Management Changes

Financial Statements

Asset Acquisitions

Clinical Trials

Investor Presentation

Conference Presentation

Meeting Adjournment

Trial Announcement

Investor Presentation

Financial Results

Patent Announcement

Warrant Agreement

FDA Guidance Received

Regulatory Approval

Warrant Adjustment

Investor Call Update

Investor Update

Business Outlook

Investor Presentation

Investor Presentation

Research Publication

Research Findings

Corporate Presentation

Investor Presentation

Clinical Trial Update

Corporate Presentation

Financial Results

Earnings Announcement

Annual Meeting Results

KOL Event Transcript

KOL Event Announcement

Investor Presentation

Positive Efficacy Data

Investor Conference

Investor Presentation

Clinical Trial Update

Public Offering

Securities Offering

Financial Results

Webcast Presentation

Investor Presentation

FDA Announcement

FDA Meeting Announcement

Clinical Trial Update

Phase 2 Study Commencement

Filing Correction

Earnings Reports

Patent Notification

Corporate Presentation

Announcement of Positive In...

AML Clinical Day

Investor Presentation

Compliance with Bid Price Rule

Patent Notification

Financial Results Announcement

Reverse Stock Split

Investor Presentation

Meeting Results

Management Changes

Securities Purchase Agreements

Investor Presentation

Earnings Reports

Earnings Reports

Clinical Trial Results

Delisting Extension

Special Meeting of Stockhol...

Clinical Trial Completion

Bylaws Amendment

Investor Presentation

Financial Results Announcement

Investigation of Short Selling

Earnings Reports

Conference Presentation

Annual Meeting of Stockholders

Earnings Reports

Clinical Trial Success

Investor Presentation

Earnings Reports

Earnings Reports

Confirmation of No Deposits...

Clinical Trial Results

Termination of Sales Agreement

External Links:

On May 6, 2025, Moleculin Biotech, Inc. announced that the World Health Organization approved "naxtarubicin" as the non-proprietary name for its new anthracycline drug, Annamycin.

AI Assistant

MOLECULIN BIOTECH INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.